Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Short Interest Update

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) was the target of a large growth in short interest in April. As of April 15th, there was short interest totaling 1,276 shares, a growth of 937.4% from the March 31st total of 123 shares. Based on an average daily trading volume, of 5,584 shares, the short-interest ratio is presently 0.2 days. Currently, 0.0% of the company’s stock are sold short.

Institutional Trading of Invesco Biotechnology & Genome ETF

A number of institutional investors have recently made changes to their positions in the business. Colonial Trust Advisors acquired a new position in Invesco Biotechnology & Genome ETF during the 4th quarter valued at about $25,000. Comerica Bank increased its holdings in shares of Invesco Biotechnology & Genome ETF by 86.2% during the fourth quarter. Comerica Bank now owns 378 shares of the company’s stock valued at $31,000 after acquiring an additional 175 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Invesco Biotechnology & Genome ETF by 74.5% during the third quarter. PNC Financial Services Group Inc. now owns 574 shares of the company’s stock valued at $40,000 after acquiring an additional 245 shares in the last quarter. NewEdge Advisors LLC raised its position in shares of Invesco Biotechnology & Genome ETF by 63.2% in the 3rd quarter. NewEdge Advisors LLC now owns 883 shares of the company’s stock valued at $62,000 after purchasing an additional 342 shares during the last quarter. Finally, Blair William & Co. IL boosted its stake in Invesco Biotechnology & Genome ETF by 150.0% in the 3rd quarter. Blair William & Co. IL now owns 1,000 shares of the company’s stock worth $70,000 after purchasing an additional 600 shares in the last quarter.

Invesco Biotechnology & Genome ETF Stock Down 0.3%

Shares of NYSEARCA PBE traded down $0.21 during trading hours on Friday, hitting $79.82. 4,381 shares of the stock were exchanged, compared to its average volume of 7,178. Invesco Biotechnology & Genome ETF has a 12 month low of $59.01 and a 12 month high of $85.73. The firm has a fifty day moving average price of $79.52 and a 200-day moving average price of $79.45. The company has a market cap of $249.84 million, a PE ratio of 20.44 and a beta of 0.76.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.